Product Code: A110993
According to a new report published by Allied Market Research, titled, "Patented Drugs Market," The patented drugs market was valued at $814.5 billion in 2022, and is estimated to reach $1,456.5 billion by 2032, growing at a CAGR of 6% from 2023 to 2032.
![Patented Drugs Market - IMG1](/sample/img/AMR1365810-f1.png)
The patented drugs market growth is driven by increase in the number of research activities for development of new drugs, advancement in biotechnology and 3D modeling, and rise in people suffering from chronic diseases. Researchers explore various disease mechanisms, molecular pathways, and drug targets to identify potential areas for therapeutic intervention. This creates opportunities for the development of new drugs which drives the growth of patented drugs market. Furthermore, the prevalence of chronic diseases, such as cardiovascular diseases, cancer, diabetes, respiratory disorders, and neurological conditions, has been steadily rising globally. For instance, in 2021 American Cancer Society (ACS), estimated that about 1.9 million new cancer cases were diagnosed in the U.S. The available patented drugs for cancer include Avastin, KYPROLIS, IBRANCE, and others. This rise in chronic diseases has led to a higher demand for effective treatments and management strategies, which in turn drives the growth of the patented drugs market.
In addition, the availability of robust regulatory authorities such as U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) determines the drug approval process and grant market exclusivity to pharmaceuticals. This exclusivity period provide advantages for pharmaceutical companies, enabling them to recover their investment and generate revenue from patented drugs. Furthermore, increase in number of patent application filing in 2022 further boost the growth of the patented drugs market. For instance, in 2022, European Patent Office (EPO), received a total of 193,460 applications. It was also reported that patent activity in pharmaceuticals increased by 1% as compared to 2021.
However, entry of generic versions of the drug at lower prices after patent expiration limit the growth of the patented drugs market. The availability of cheaper alternatives may impact the demand for patented drugs. Furthermore, high costs associated with new drug development is financially challenging for pharmaceutical companies and limit their ability to invest in innovation and develop new patented drugs thereby impacting the market growth. On the other hand, surge in technological advancements, such as precision medicine, genomics, proteomics, and targeted therapies, are revolutionizing drug discovery and development. These advancements enable the development of more effective and patented drugs during the forecast period.
The patented drugs market is segmented on the basis of dosage form, indication, distribution channel, and region. On the basis of dosage form, the market is classified into solid drug product, liquid drug product, and others. Others segments include semi-solid drug and gaseous drug. As per indication, the market is categorized into cardiovascular diseases, cancer, autoimmune diseases, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global patented drugs market are AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, AstraZeneca plc, Bayer AG, Johnson & Johnson, F. Hoffmann-La Roche AG, Astellas Pharma Inc., and Biogen. Key players operating in the market have adopted patent and patent extension as their key strategies to expand their market share and product portfolio.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the patented drugs market analysis from 2022 to 2032 to identify the prevailing patented drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the patented drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global patented drugs market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Distribution Channel
- Hospital Pharmacies
- Drug Store and Retail Pharmacies
- Online Pharmacies
By Dosage Form
- Solid Drug Product
- Liquid Drug Product
- Others
By Indication
- Cardiovascular Diseases
- Cancer
- Autoimmune Diseases
- Others
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- Amgen Inc.
- Pfizer Inc.
- AstraZeneca plc
- Bayer AG
- Biogen
- Johnson & Johnson
- Astellas Pharma Inc.
- F. Hoffmann-La Roche AG
- Novartis AG
- AbbVie Inc.
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in investment in research and development activities
- 3.4.1.2. Surge in disease burden
- 3.4.2. Restraints
- 3.4.2.1. High cost of patented drugs
- 3.4.3. Opportunities
- 3.4.3.1. Strong intellectual property rights
- 3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PATENTED DRUGS MARKET, BY DOSAGE FORM
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Solid Drug Product
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Liquid Drug Product
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
CHAPTER 5: PATENTED DRUGS MARKET, BY INDICATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Cardiovascular Diseases
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Cancer
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Autoimmune Diseases
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- 5.5. Others
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
CHAPTER 6: PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Drug Store and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
CHAPTER 7: PATENTED DRUGS MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Dosage Form
- 7.2.3. Market size and forecast, by Indication
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Dosage Form
- 7.2.5.1.3. Market size and forecast, by Indication
- 7.2.5.1.4. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Dosage Form
- 7.2.5.2.3. Market size and forecast, by Indication
- 7.2.5.2.4. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Dosage Form
- 7.2.5.3.3. Market size and forecast, by Indication
- 7.2.5.3.4. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Dosage Form
- 7.3.3. Market size and forecast, by Indication
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Dosage Form
- 7.3.5.1.3. Market size and forecast, by Indication
- 7.3.5.1.4. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Dosage Form
- 7.3.5.2.3. Market size and forecast, by Indication
- 7.3.5.2.4. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Dosage Form
- 7.3.5.3.3. Market size and forecast, by Indication
- 7.3.5.3.4. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Dosage Form
- 7.3.5.4.3. Market size and forecast, by Indication
- 7.3.5.4.4. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Dosage Form
- 7.3.5.5.3. Market size and forecast, by Indication
- 7.3.5.5.4. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Dosage Form
- 7.3.5.6.3. Market size and forecast, by Indication
- 7.3.5.6.4. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Dosage Form
- 7.4.3. Market size and forecast, by Indication
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Dosage Form
- 7.4.5.1.3. Market size and forecast, by Indication
- 7.4.5.1.4. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Dosage Form
- 7.4.5.2.3. Market size and forecast, by Indication
- 7.4.5.2.4. Market size and forecast, by Distribution Channel
- 7.4.5.3. India
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Dosage Form
- 7.4.5.3.3. Market size and forecast, by Indication
- 7.4.5.3.4. Market size and forecast, by Distribution Channel
- 7.4.5.4. Australia
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Dosage Form
- 7.4.5.4.3. Market size and forecast, by Indication
- 7.4.5.4.4. Market size and forecast, by Distribution Channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Dosage Form
- 7.4.5.5.3. Market size and forecast, by Indication
- 7.4.5.5.4. Market size and forecast, by Distribution Channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Dosage Form
- 7.4.5.6.3. Market size and forecast, by Indication
- 7.4.5.6.4. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Dosage Form
- 7.5.3. Market size and forecast, by Indication
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Dosage Form
- 7.5.5.1.3. Market size and forecast, by Indication
- 7.5.5.1.4. Market size and forecast, by Distribution Channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Dosage Form
- 7.5.5.2.3. Market size and forecast, by Indication
- 7.5.5.2.4. Market size and forecast, by Distribution Channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Dosage Form
- 7.5.5.3.3. Market size and forecast, by Indication
- 7.5.5.3.4. Market size and forecast, by Distribution Channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Dosage Form
- 7.5.5.4.3. Market size and forecast, by Indication
- 7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
- 9.1. AbbVie Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.2. Amgen Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. Pfizer Inc.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. Novartis AG
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. AstraZeneca plc
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. Bayer AG
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Johnson & Johnson
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. F. Hoffmann-La Roche AG
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Biogen
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. Astellas Pharma Inc.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance